Medtronic plc (MDT)
Kuros Biosciences USA, Inc. Announces an Exclusive Strategic Agreement with the Medtronic Spinal Division
Medtronic will act as the exclusive sales agent of MagnetOsTM for Kuros Biosciences USA, Inc. in mutually agreed upon sales territories for use in spine surgeries Kuros will work collaboratively to sell, market and provide support services to Medtronic's sales force Kuros will keep responsibility for contracts, hospital partnerships and the recognition of revenue from sales Kuros will continue to sell directly in non-contracted territories as well as in markets outside of spine This agreement transforms an initial trial agreement into a strategic alliance SCHLIEREN, SWITZERLAND / ACCESSWIRE / January 7, 2025 / Kuros Biosciences USA Inc., ("Kuros"), a wholly owned subsidiary of Kuros Biosciences AG, a global leader in advanced musculoskeletal bone healing technologies, today announced a strategic five-year, exclusive sales agency agreement with Medtronic, a leading global healthcare technology company. The agreement provides Medtronic with exclusivity in certain spine geographies within the U.S. market, underscoring a shared commitment to expanding access to Kuros' pioneering MagnetOs bone grafting technology.
Medtronic: A Dividend Aristocrat That's Poised To Pop
Medtronic offers value and income potential with a 3.5% dividend yield, strong fundamentals, and 47 years of consecutive dividend increases. Despite recent share price underperformance, MDT shows solid revenue and EPS growth driven by innovation in high-growth healthcare segments. MDT's forward P/E ratio of 14.9 is well below its historical average, indicating potential for valuation upside.
Here's Why Medtronic (MDT) Gained But Lagged the Market Today
Medtronic (MDT) closed at $80.95 in the latest trading session, marking a +0.91% move from the prior day.
Reasons to Retain Medtronic Stock in Your Portfolio Now
Investors continue to be optimistic about MDT due to its impressive Neuroscience portfolio. Yet, the dull macroeconomic scenario poses a concern to the company's margins.
5 Top AI-in-MedTech Stocks for Big Gains in 2025: MDT, BSX & More
Here we discuss five medical stocks - MDT, BSX, BDX, GEHC and TEM - incorporating AI in their workflows. These are likely to gain in 2025 as AI helps cut costs and improve patient care.
Medtronic Stock Is Still A Great "Buy"
Medtronic remains a "Buy" due to its undervalued stock, recent product launches, and resolved supply chain issues, despite underperformance over the past 7 months. The company posted solid Q2 results with revenue up 5.25% YoY and expects organic revenue growth of 4.75%-5% for fiscal 2025. Medtronic's strategic acquisitions and focus on innovation and efficiency are expected to drive sustainable growth and improve margins over the next 1-3 years.
4 Dividend Stocks to Double Up on Right Now
You can pat yourself on the back if you're thinking of loading up your portfolio with dividend-paying stocks -- because they're surprisingly strong wealth builders. (If you weren't thinking of doing so, you can start now!
Medtronic Stock Declines 5.6% in a Month: Time to Buy the Dip?
MDT stock suffers as a result of geopolitical complications and supply issues despite an expanding portfolio and strong strategic executions.
2 Robotic Surgery Stocks Challenging Intuitive Surgical's Lead
Robotic surgery used to be fodder for science fiction movies. Not anymore.
2 Healthcare Dividend Stocks to Hold for the Long Haul
Investors looking for stocks to hold on to for a while might want to consider dividend-paying companies. Besides offering a regular stream of passive income, dividend stocks have generally outperformed their non-dividend peers over the long run.
Medtronic: Guidance Raised, Solid Dividend, Shares Still A Bargain
Medtronic remains a buy due to its attractive valuation and steady EPS growth, despite recent sector-wide selling pressure and modest losses. Q2 results beat Wall Street expectations, with revenue up 5% year-over-year, and management raised FY 2025 revenue and earnings estimates. Key risks include supply chain issues, competition, policy changes, and currency fluctuations, but MDT's free cash flow yield and technical support levels are strong.
Reasons to Retain Medtronic Stock in Your Portfolio Now
Investors continue to be optimistic about MDT due to its impressive international expansion. Yet, the dull macroeconomic scenario poses a concern to the company's margins.
